Cargando…

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal transduction system, are long-established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a particularly high number of clinical trials involving PDE inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bondarev, Andrey D., Attwood, Misty M., Jonsson, Jörgen, Chubarev, Vladimir N., Tarasov, Vadim V., Liu, Wen, Schiöth, Helgi B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731127/ https://www.ncbi.nlm.nih.gov/pubmed/36506513 http://dx.doi.org/10.3389/fphar.2022.1057083

Ejemplares similares

Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
por: Nazarova, Victoria A., et al.
Publicado: (2022)

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
por: Dahlén, Amelia D., et al.
Publicado: (2022)

The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
por: Namiot, Eugenia D., et al.
Publicado: (2023)

Pharmacogenetics in Primary Headache Disorders
por: Belyaeva, Irina I., et al.
Publicado: (2022)

Advances in the development of new biomarkers for Alzheimer’s disease
por: Klyucherev, Timofey O., et al.
Publicado: (2022)

Stem Cells in Clinical Trials on Neurological Disorders: Trends in Stem Cells Origins, Indications, and Status of the Clinical Trials
por: Namiot, Eugenia D., et al.
Publicado: (2022)

Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines
por: Namiot, Eugenia D., et al.
Publicado: (2023)

Classification of Trispanins: A Diverse Group of Proteins That Function in Membrane Synthesis and Transport Mechanisms
por: Attwood, Misty M., et al.
Publicado: (2020)

Characterization of Five Transmembrane Proteins: With Focus on the Tweety, Sideroflexin, and YIP1 Domain Families
por: Attwood, Misty M., et al.
Publicado: (2021)

Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review
por: Zobdeh, Farzin, et al.
Publicado: (2022)

The Epigenetics of Migraine
por: Zobdeh, Farzin, et al.
Publicado: (2023)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
por: Janosova, Viera, et al.
Publicado: (2020)

Alterations of Astrocytes in the Context of Schizophrenic Dementia
por: Tarasov, Vadim V., et al.
Publicado: (2020)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Highly diversified expansions shaped the evolution of membrane bound proteins in metazoans
por: Attwood, Misty M., et al.
Publicado: (2017)

Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors
por: Joskova, Marta, et al.
Publicado: (2020)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
por: Kawamatawong, Theerasuk
Publicado: (2021)

High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis
por: Affatato, Oreste, et al.
Publicado: (2021)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors
por: Lee, Sang-Yong, et al.
Publicado: (2017)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Topology based identification and comprehensive classification of four-transmembrane helix containing proteins (4TMs) in the human genome
por: Attwood, Misty M., et al.
Publicado: (2016)

Synthesis of an insulin-loaded mucoadhesive nanoparticle designed for intranasal administration: focus on new diffusion media
por: Jamshidnejad-Tosaramandani, Tahereh, et al.
Publicado: (2023)

The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review
por: Ahmad, Nazir, et al.
Publicado: (2022)

Increased Pain Sensitivity in Obese Patients After Lung Cancer Surgery
por: Majchrzak, Maciej, et al.
Publicado: (2019)

Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges
por: Bansal, Isha, et al.
Publicado: (2023)

Dissecting the Molecular Mechanisms Surrounding Post-COVID-19 Syndrome and Neurological Features
por: Mohamed, Mohamed S., et al.
Publicado: (2022)

Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases
por: Mokry, Juraj, et al.
Publicado: (2021)

East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease
por: Sharma, Manju, et al.
Publicado: (2018)

In Vitro, In Vivo and In Silico Effectiveness of LASSBio-1386, an N-Acyl Hydrazone Derivative Phosphodiesterase-4 Inhibitor, Against Leishmania amazonensis
por: Silva, Dahara Keyse Carvalho, et al.
Publicado: (2020)

Editorial: Cyclic Nucleotide Phosphodiesterases (PDEs) in Immune Regulation and Inflammation
por: Brocke, Stefan, et al.
Publicado: (2022)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice
por: Yanai, Shuichi, et al.
Publicado: (2022)

Small Molecule Inhibitors of CRM1
por: Ferreira, Bibiana I., et al.
Publicado: (2020)

Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation
por: TAJIMA, Tsuyoshi, et al.
Publicado: (2018)

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis
por: Totani, Licia, et al.
Publicado: (2021)

Editorial: Recent advances in novel therapeutic molecules and targets for inflammatory diseases
por: Li, Feng, et al.
Publicado: (2023)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

The regulatory role of AP-2β in monoaminergic neurotransmitter systems: insights on its signalling pathway, linked disorders and theragnostic potential
por: Al-Sabri, Mohamed H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3bakg5jors4uef2bcgnqjka5sv